Zenshine Pharmaceuticals

Developer of small molecules drug for the treatment of cancer

placeHangzhou, Zhejiang, China calendar_todayFounded 2018 language zenshine-pharma.com

Innovation

2 patent families (2 granted) — focus: Chemistry & metallurgy; filing pace active. Cited 7 times.

YearFilings
20251
20261

Investor mix

6 investors on record; lead investors include SDIC, Matrix Partners China, LYZZ Capital.

Investor typeCountShare
Venture capital467%
Bank & private debt117%
Other / undisclosed117%
Coming soon